Amsterdam UMC spin-off PacingCure is the winner of the Venture Challenge at the online edition of the Dutch Life Science Conference on the 26th of November. PacingCure develops precision gene therapies for common cardiac arrhythmias and cardiomyopathies, aiming to restore the natural pacing of the heart. The company is founded on combined research from the departments of Cardiology and Medical Biology of the AMC.
The PacingCure team, consisting of Geert Boink, Hanno Tan and Osne Kirzner, participated in the summer edition of the Venture Challenge. In this 10-week bootcamp program, life science start-ups work to sharpen and validate their business idea. During the program, the participating start-ups produce a venture plan and pitch their business in front of an expert jury. This year, the jury consisting of Carine van den Brink, Eline Vrijland, Andre van de Sande, Kim Lucassen and Geert-Jan Mulder, agreed that “PacingCure is addressing a high unmet medical need that they can target with their gene-therapy. They have identified a clear first orphan indication to prove their technique. Moreover, they are a very experienced team of clinicians.”
PacingCure is awarded €25.000,- in price money that they will invest in the further growth of their company. The vision of the company is to become a world leader in cardiac gene therapy.
PacingCure is developing therapies that offer superior treatment over established implantable and medicinal therapies to patients suffering from severe morbidity and mortality, and a cure for patients who are currently untreatable. Their in-vivo validated gene therapies are injected directly into a small region of the heart using a simple, minimal-invasive procedure.
VU startup Sports-f(x) is uitgeroepen tot winnaar van de 12e Dutch Sports Innovation Award 2020. Oprichter Nilas van Woersem ontving de prijs uit handen van jurylid Jan Hoefnagels voor de NextRound Boxing Bag, een slimme bokszak die direct feedback geeft. De Dutch Sports Innovation Award is de stimuleringsprijs voor een innovatief en kansrijk product of […]
NewsIn their quest of creating safe and effective immunotherapy cancer treatments, VU spinoff LUMICKS and Amsterdam UMC spinoff LAVA Therapeutics joined forces. The partnership aims to evaluate the efficacy of various tumor-specific γδ T-cell engagers based on the resulting binding strengths (cell avidity) between T cells and tumors, measured with LUMICKS newly installed z-Movi® Cell […]
NewsThe ten winners of the prestigious Academic Startup Competition 2020 can use the title ‘Best Academic Startup of 2020’ for the coming year. The winning startups were chosen by an expert jury after a thrilling final in which all 20 finalists were asked to pitch. The ten winners were chosen on the basis of their value proposition, the […]
News